CURIS INC (CRIS) Stock Price, Forecast & Analysis
NASDAQ:CRIS • US2312693094
CRIS Key Statistics, Chart & Performance
The current stock price of CRIS is 1.1374 USD. In the past month the price increased by 21.07%. In the past year, price decreased by -64.29%.
CRIS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CRIS. When comparing the yearly performance of all stocks, CRIS is a bad performer in the overall market: 91.25% of all stocks are doing better.
CRIS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CRIS. CRIS may be in some trouble as it scores bad on both profitability and health.
CRIS Financial Highlights
Over the last trailing twelve months CRIS reported a non-GAAP Earnings per Share(EPS) of -3.67. The EPS increased by 53.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CRIS Forecast & Estimates
11 analysts have analysed CRIS and the average price target is 14.28 USD. This implies a price increase of 1155.49% is expected in the next year compared to the current price of 1.1374.
For the next year, analysts expect an EPS growth of 63.06% and a revenue growth 17.66% for CRIS
CRIS Ownership
CRIS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.05 | 409.148B | ||
| AMGN | AMGEN INC | 16.44 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.27 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.95 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.4 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.46 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 13 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.13 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRIS
Company Profile
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
Company Info
CURIS INC
128 Spring Street, Building C, Suite 500
Lexington MASSACHUSETTS 02421 US
CEO: James Dentzer
Employees: 34
Phone: 13026587581
CURIS INC / CRIS FAQ
What does CRIS do?
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 33 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.
What is the stock price of CURIS INC today?
The current stock price of CRIS is 1.1374 USD. The price decreased by -1.1% in the last trading session.
Does CURIS INC pay dividends?
CRIS does not pay a dividend.
What is the ChartMill rating of CURIS INC stock?
CRIS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in CURIS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRIS.
What is the expected growth for CRIS stock?
The Revenue of CURIS INC (CRIS) is expected to grow by 17.66% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for CURIS INC?
CURIS INC (CRIS) has a market capitalization of 14.71M USD. This makes CRIS a Nano Cap stock.